We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+66.43%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$489M
AUM Growth
-$16.5M
Cap. Flow
-$88.1M
Cap. Flow %
-18.03%
Top 10 Hldgs %
36.36%
Holding
114
New
25
Increased
12
Reduced
45
Closed
25

Top Buys

Rank Stock Value
1
SPRB
Spruce Biosciences
SPRB
+$14.1M
2
AZN icon
AstraZeneca
AZN
+$13.9M
3
SNY icon
Sanofi
SNY
+$10.9M
4
UHS icon
Universal Health Services
UHS
+$10.1M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$9.73M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$17M
2
MCK icon
McKesson
MCK
+$11.8M
3
MOH icon
Molina Healthcare
MOH
+$9.7M
4
AMN icon
AMN Healthcare
AMN
+$9.23M
5
CAH icon
Cardinal Health
CAH
+$8.68M

Sector Composition

Rank Sector Weight
1 Healthcare 81.67%
2 Technology 1.08%
3 Consumer Staples 0.76%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
51
DELISTED
Cymabay Therapeutics
CBAY
$3.37M 0.69%
587,339
-571,897
-49% -$4.33M
OBIO icon
52
Orchestra BioMed
OBIO
$249M
$3.2M 0.66%
250,000
– –
EUCRU
53
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$3.2M 0.65%
+300,000
New +$3.05M
VINC
54
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$3.13M 0.64%
+7,495
New +$2.36M
VRAY
55
DELISTED
ViewRay, Inc.
VRAY
$2.96M 0.61%
775,000
-1,263,175
-62% -$4.47M
ANIK icon
56
Anika Therapeutics
ANIK
$270M
$2.96M 0.61%
65,382
-28,720
-31% -$1.09M
CRDF icon
57
Cardiff Oncology
CRDF
$74.7M
$2.69M 0.55%
+149,833
New +$2.63M
CNST
58
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$2.66M 0.55%
+92,500
New +$2.33M
DTIL icon
59
Precision BioSciences
DTIL
$191M
$2.65M 0.54%
10,588
-1,277
-11% -$313K
ASLN
60
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$2.55M 0.52%
34,816
+392
+1% +$28.8K
IOVA icon
61
Iovance Biotherapeutics
IOVA
$2.77B
$2.51M 0.51%
+54,000
New +$2.14M
SIOX
62
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.46M 0.5%
+886,665
New +$2.58M
AVTX icon
63
Avalo Therapeutics
AVTX
$989M
$2.45M 0.5%
322
-36
-10% -$250K
OTRK
64
DELISTED
Ontrak
OTRK
$2.36M 0.48%
+425
New +$2.32M
VAPO
65
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$2.09M 0.43%
+9,713
New +$2.17M
BCEL
66
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.08M 0.42%
128,455
+49,687
+63% +$745K
NBSE
67
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$2.05M 0.42%
14,685
-534
-4% -$86.5K
FUSN
68
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.03M 0.42%
+172,693
New +$2.17M
AYLA
69
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$1.72M 0.35%
156,655
-3,311
-2% -$38.2K
FULC icon
70
Fulcrum Therapeutics
FULC
$288M
$1.71M 0.35%
+146,272
New +$1.65M
ONCT
71
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$1.58M 0.32%
+16,167
New +$1.02M
AGIO icon
72
Agios Pharmaceuticals
AGIO
$1.91B
$1.52M 0.31%
35,000
-21,000
-38% -$830K
DCOY
73
Decoy Therapeutics
DCOY
$2.16M
$1.51M 0.31%
+46
New +$1.35M
SYRE icon
74
Spyre Therapeutics
SYRE
$9.12B
$1.5M 0.31%
7,644
-800
-9% -$166K
ODT
75
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$1.45M 0.3%
75,500
-59,500
-44% -$918K
1 2
3
4 5

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return
ACM
Academy Capital Management Waco, Texas $699M AUM 12.08% 1-Year Est. Return

Sio Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sio Capital Management held 114 positions worth $489M, down 3.3% from $505M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sio Capital Management withdrew a net $88.1M in Q4 2020, closing 25 positions and reducing 45 holdings. Its most notable exit was Johnson & Johnson, an estimated $17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sio Capital Management opened a new position in Spruce Biosciences worth $15.5M.

  • Sio Capital Management's largest Q4 2020 buy was Spruce Biosciences: 8,489 shares worth $15.5M.
  • Sio Capital Management added most to Kura Oncology in Q4 2020, an estimated $3.55M increase.
  • Sio Capital Management's biggest Q4 2020 reduction was McKesson, cutting an estimated $11.8M.
  • Sio Capital Management fully exited Johnson & Johnson in Q4 2020, selling an estimated $17M.
  • Sio Capital Management's ten largest holdings make up 36% of its $489M portfolio in Q4 2020.
  • Sio Capital Management opened 25 new positions and closed 25 in Q4 2020.
  • Sio Capital Management's portfolio value fell 3.3% quarter-over-quarter to $489M.

Based on Sio Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.